{
  "docId": "019de074-d3d5-753e-80c7-2426b111c999",
  "docSlug": "1ec46bbfcfe4d48ad79d6f74349ca67d",
  "documentTitle": "ATAI | Investor Conference Presentation Deck | 14 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 13,
  "pageCount": 14,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses topographical brain maps to visualize EEG data changes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d3d5-753e-80c7-2426b111c999/13",
  "deckHref": "/decks/019de074-d3d5-753e-80c7-2426b111c999",
  "deckJsonHref": "/decks/019de074-d3d5-753e-80c7-2426b111c999.json",
  "deckAnchorHref": "/decks/019de074-d3d5-753e-80c7-2426b111c999#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Topographical EEG maps for Placebo, Low Doses, and High Doses",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c996ed8b-ab52-4be9-a975-a4aa269454e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.83
      },
      "kind": "paragraph",
      "text": "Channels with significant differences (paired t-test; p<0.05, after FDR correction for multiple comparison) are marked with black circles. Topographical maps show distribution of beta power (13-30 Hz) across the scalp.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5337ed09-8450-4386-b05a-6b36826f4bca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: FDR = False Discovery Rate, EEG = Electroencephalogram. 1. Power is NOT in log scale and the unit of measurement is uV2. 2. Given twice daily every 12 hours",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd4da7c7-6c06-428c-9f56-9a6d21f3ba9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "GRX-917 Phase 1 data: Dose-dependent increase in frontal beta power was demonstrated, providing evidence of target engagement and mechanism of action",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cee2654-66d2-475c-86d4-515c372ba1d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Heatmap matrix",
      "slug": "heatmap-matrix",
      "agent": null,
      "layer": "slide",
      "matchId": "39cf016f-7523-4ce8-b96d-5aad16374342",
      "evidence": "Topographical EEG maps for Placebo, Low Doses, and High Doses",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}